Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study

被引：0
|
作者：
Hanfang Jiang
Huiping Li
Guohong Song
Lijun Di
Bin Shao
Ying Yan
Xiaoran Liu
Yifei Chen
Ruyan Zhang
Ran Ran
Yaxin Liu
Xinyu Gui
Nan Wang
Huan Wang
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology
来源：
Breast Cancer Research and Treatment | 2023年 / 199卷
关键词：
Pegylated liposomal doxorubicin; Metastatic breast cancer; HER2-negative; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：67 / 79
页数：12
相关论文
共 50 条
  • [41] A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer
    Jagiello-Gruszfeld, Agnieszka
    Tjulandin, Sergei
    Dobrovolskaya, Natalya
    Manikhas, Alexey
    Pienkowski, Tadeusz
    DeSilvio, Michelle
    Ridderheim, Mona
    Abbey, Rowena
    ONCOLOGY, 2010, 79 (1-2) : 129 - 135
  • [42] A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline
    Hong, Ruey-Long
    Lin, Ching-Hung
    Chao, Tsu-Yi
    Kao, Woei-You
    Wang, Cheng-Hsu
    Hsieh, Ruey Kuen
    Hwang, Wei-Shou
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 847 - 853
  • [43] Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial
    R. Murialdo
    F. Bertolotti
    G. Pastorino
    M. Mencoboni
    M. Bergaglio
    U. Folco
    N. Cinzia
    F. Vaira
    C. Simoni
    L. Canobbio
    M. Parodi
    Fulvio Brema
    Alberto Ballestrero
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1009 - 1016
  • [44] Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial
    Murialdo, R.
    Bertolotti, F.
    Pastorino, G.
    Mencoboni, M.
    Bergaglio, M.
    Folco, U.
    Cinzia, N.
    Vaira, F.
    Simoni, C.
    Canobbio, L.
    Parodi, M.
    Brema, Fulvio
    Ballestrero, Alberto
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (04) : 1009 - 1016
  • [45] A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline
    Ruey-Long Hong
    Ching-Hung Lin
    Tsu-Yi Chao
    Woei-You Kao
    Cheng-Hsu Wang
    Ruey Kuen Hsieh
    Wei-Shou Hwang
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 847 - 853
  • [46] Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
    Rochlitz, C.
    Ruhstaller, T.
    Lerch, S.
    Spirig, C.
    Huober, J.
    Suter, T.
    Buehlmann, M.
    Fehr, M.
    Schoenenberger, A.
    von Moos, R.
    Winterhalder, R.
    Rauch, D.
    Mueller, A.
    Mannhart-Harms, M.
    Herrmann, R.
    Cliffe, B.
    Mayer, M.
    Zaman, K.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 80 - 85
  • [47] A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)
    Coleman, RE
    Biganzoli, L
    Canney, P
    Dirix, L
    Mauriac, L
    Chollet, P
    Batter, V
    Ngalula-Kabanga, E
    Dittrich, C
    Piccart, M
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (07) : 882 - 887
  • [48] Comparison of the efficacy and safety of pegylated liposomal doxorubicin and epirubicin in neoadjuvant chemotherapy for HER2-negative breast cancer: a real-world case-control study
    Yang, Lixian
    Zhang, Shiyu
    Zheng, Lei
    Pu, Pengpeng
    Li, Xiaowei
    Jia, Lining
    INTERNATIONAL JOURNAL OF SURGERY-ONCOLOGY, 2024, 9 (01): : 10 - 14
  • [49] Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study
    Tseng, Ling-Ming
    Chen, Fang Ming
    Chen, Shou-Tung
    Cheng, Fiona Tsui-Fen
    Chao, Tsu-Yi
    Dai, Ming-Shen
    Kao, Woei-Yau
    Yeh, Ming-Hsin
    Chen, Dar-Ren
    Liu, Liang-Chih
    Wang, Hewi Chung
    Chang, Hong-Tai
    Wang, Being Whey
    Yu, Jyh-Cherng
    Chen, Shin Cheh
    Liao, Guo-Shiou
    Hou, Ming-Feng
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (10) : 484 - 494
  • [50] Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: fi nal results from a phase I/II, single-arm, basket trial
    Kalinsky, K.
    Diamond, J. R.
    Vahdat, L. T.
    Tolaney, S. M.
    Juric, D.
    O'Shaughnessy, J.
    Moroose, R. L.
    Mayer, I. A.
    Abramson, V. G.
    Goldenberg, D. M.
    Sharkey, R. M.
    Maliakal, P.
    Hong, Q.
    Goswami, T.
    Wegener, W. A.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2020, 31 (12) : 1709 - 1718
12345